Ruximonab 100 mg Injection 10 ml is classified as a monoclonal antibody medication used for treating non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Additionally, this medication is utilized in the management of rheumatoid arthritis when combined with methotrexate, as well as granulomatosis in conjunction with glucocorticoids. It is also effective in treating Pemphigus Vulgaris (PV) and mature B-cell acute leukaemia (B-AL).
The active ingredient in Ruximonab 100 mg Injection 10 ml is Rituximab, which functions by inhibiting the transcription of DNA and RNA necessary for the proliferation of cancer cells. This action helps to hinder the growth and dissemination of both cancerous and non-cancerous cells. Furthermore, Ruximonab 100 mg Injection 10 ml disrupts the immune response that leads to inflammation in joint tissues, thereby alleviating pain and inflammation while preventing joint damage and the progression of the disease over time.
Potential side effects of Ruximonab 100 mg Injection 10 ml may include pale skin, painful urination, night sweats, flushing, back pain, nausea, vomiting, diarrhea, abdominal pain, mouth sores, skin peeling, reactions at the injection site, and discomfort at the injection location. These side effects typically do not necessitate medical intervention and tend to resolve on their own. However, if any side effects persist or worsen, it is advisable to consult a healthcare professional. Ruximonab 100 mg Injection 10 ml is administered parenterally by a qualified healthcare provider, so self-administration is not recommended.
Ruximonab 100 mg Injection 10 ml should be avoided if you have an allergy to it or any of its components. Make sure to inform your doctor about your complete medical history, including any current medications, to eliminate the possibility of side effects or interactions. Additionally, let your doctor know if you have liver or kidney disease, a hepatitis B virus infection, heart conditions, any active infections, or gastrointestinal disorders prior to receiving this injection. Ruximonab 100 mg Injection 10 ml may lead to bowel obstruction and perforation, reactivation of Hepatitis B infection, cardiac arrhythmias, tumor lysis syndrome, and angina in certain patients. Therefore, careful monitoring is essential throughout the treatment process. Notify your doctor if you are pregnant, planning to become pregnant, or are breastfeeding.
